Les anti-inflammatoires et SARS-CoV-2 (COVID-19)

To date, treatment options for severe COVID-19 remain limited and there is currently no effective drug or vaccine for the treatment or prevention of specific SARS-CoV-2 to treat critically ill patients. A new treatment strategy, in addition to antiviral therapy alone, may be required to have a signi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moutaouakkil, Youssef, Tadlaoui, Yasmina, Latt, Esso Eric Valery, Atbib, Yassine, Cherrah, Yahia, Bennana, Ahmed, Bousliman, Yassir, Lamsaouri, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252016/
http://dx.doi.org/10.1016/j.douler.2020.04.012
_version_ 1783539070160338944
author Moutaouakkil, Youssef
Tadlaoui, Yasmina
Latt, Esso Eric Valery
Atbib, Yassine
Cherrah, Yahia
Bennana, Ahmed
Bousliman, Yassir
Lamsaouri, Jamal
author_facet Moutaouakkil, Youssef
Tadlaoui, Yasmina
Latt, Esso Eric Valery
Atbib, Yassine
Cherrah, Yahia
Bennana, Ahmed
Bousliman, Yassir
Lamsaouri, Jamal
author_sort Moutaouakkil, Youssef
collection PubMed
description To date, treatment options for severe COVID-19 remain limited and there is currently no effective drug or vaccine for the treatment or prevention of specific SARS-CoV-2 to treat critically ill patients. A new treatment strategy, in addition to antiviral therapy alone, may be required to have a significant impact on clinical outcomes. Immunomodulatory therapy to downregulate cytokine shock may provide information on the treatment of COVID-19. Combined use of an immunomodulatory agent with an antiviral agent may give doctors more time to provide supportive therapy to patients with COVID-19. In this review of the literature, the roles of several anti-inflammatory drugs were reviewed to explore their effectiveness in the fight against SARS-CoV-2.
format Online
Article
Text
id pubmed-7252016
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-72520162020-05-28 Les anti-inflammatoires et SARS-CoV-2 (COVID-19) Moutaouakkil, Youssef Tadlaoui, Yasmina Latt, Esso Eric Valery Atbib, Yassine Cherrah, Yahia Bennana, Ahmed Bousliman, Yassir Lamsaouri, Jamal Douleurs Article To date, treatment options for severe COVID-19 remain limited and there is currently no effective drug or vaccine for the treatment or prevention of specific SARS-CoV-2 to treat critically ill patients. A new treatment strategy, in addition to antiviral therapy alone, may be required to have a significant impact on clinical outcomes. Immunomodulatory therapy to downregulate cytokine shock may provide information on the treatment of COVID-19. Combined use of an immunomodulatory agent with an antiviral agent may give doctors more time to provide supportive therapy to patients with COVID-19. In this review of the literature, the roles of several anti-inflammatory drugs were reviewed to explore their effectiveness in the fight against SARS-CoV-2. Elsevier Masson SAS. 2020-04 2020-05-01 /pmc/articles/PMC7252016/ http://dx.doi.org/10.1016/j.douler.2020.04.012 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Moutaouakkil, Youssef
Tadlaoui, Yasmina
Latt, Esso Eric Valery
Atbib, Yassine
Cherrah, Yahia
Bennana, Ahmed
Bousliman, Yassir
Lamsaouri, Jamal
Les anti-inflammatoires et SARS-CoV-2 (COVID-19)
title Les anti-inflammatoires et SARS-CoV-2 (COVID-19)
title_full Les anti-inflammatoires et SARS-CoV-2 (COVID-19)
title_fullStr Les anti-inflammatoires et SARS-CoV-2 (COVID-19)
title_full_unstemmed Les anti-inflammatoires et SARS-CoV-2 (COVID-19)
title_short Les anti-inflammatoires et SARS-CoV-2 (COVID-19)
title_sort les anti-inflammatoires et sars-cov-2 (covid-19)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252016/
http://dx.doi.org/10.1016/j.douler.2020.04.012
work_keys_str_mv AT moutaouakkilyoussef lesantiinflammatoiresetsarscov2covid19
AT tadlaouiyasmina lesantiinflammatoiresetsarscov2covid19
AT lattessoericvalery lesantiinflammatoiresetsarscov2covid19
AT atbibyassine lesantiinflammatoiresetsarscov2covid19
AT cherrahyahia lesantiinflammatoiresetsarscov2covid19
AT bennanaahmed lesantiinflammatoiresetsarscov2covid19
AT bouslimanyassir lesantiinflammatoiresetsarscov2covid19
AT lamsaourijamal lesantiinflammatoiresetsarscov2covid19

Ejemplares similares